All set? Ready?
Yes.
Hi, everyone. My name is Maury Raycroft, and one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Hemab, Benny Sørensen. Thanks so much for joining us today, Benny.
Thank you for having us.
We are going to do a fireside chat format. For those who are new to the story, if you can give a brief intro to COAG.
Sure. Hemab Therapeutics is a biotech company where we are pursuing a vision of reimagining treatment of blood coagulation disorders. It is a biotech company exclusively focused in coagulation, hence the COAG ticker. We are proud of the progress we have made. We have a molecule, sutacimig, that is now in phase III pivotal trials in Glanzmann thrombasthenia. Same molecule is being prosecuted in a second indication called Factor VII deficiency, where we have phase II data coming soon. I am sure we will chat about that. Then the second asset, HMB-002, is a molecule for prophylaxis for von Willebrand disease. Then our latest, HMB-003, is for heavy menstrual bleeding.
Yep. Yeah, it is a great intro. Maybe let us start off with sutacimig for Glanzmann. You just announced the start of your phase III study. We saw the trials posted on ClinicalTrials.gov a couple of days ago. FDA recommended considering a randomized controlled study while acknowledging the feasibility challenges in Glanzmann. Can you provide more color on the feedback and whether any specifics related to how the single-arm study should be run were discussed?
Sure. We have had really constructive dialogue with the regulatory authorities here, and discussed what would be the best way to kind of advance sutacimig as a first-ever prophylactic treatment for Glanzmann. I think it is not unusual that regulators would kind of like, "Have you considered a randomized trial versus a single-arm trial?" The dialogue has been very constructive. It is very clear based on the phase II data we have, that we need to somewhat control a substantial amount of variability. The strongest way of doing that is a single-arm trial. It will enable us to do a 90% power for a minimum 50% effect. We think that is super important to kind of minimize the technical risk to really give the largest possible hope for these patients in having a first-ever prophylactic treatment.
Yeah. Makes sense. As far as the endpoints go and everything, you are not compromising anything there?
No, we are fully aligned on the primary endpoint being the annualized treated bleed rate. We have collaborated really closely with the agency, building a really state-of-the-art electronic validated bleed diary that gives us an opportunity to collect this data with really high quality. So, primary endpoint, all secondary endpoint fully endorsed with the regulators. Our approach to analyzing the data, long time ago we agreed on the dose, the dose regime. Hey, there's a lot more that we agree on than we are still discussing.
Makes sense. As you get the phase III started in the U.S., maybe talk about the status ex-U.S., and it's an ultra-rare disease. How many sites do you need for this study? You're going to have 75 patients.
Yeah. So it's approximately 75 patients. We've spent almost a half a year building a really deep understanding of feasibility. We have identified multiple more patients than the 75 that we need to enroll. You can expect this to be enrolled in multiple countries and multiple sites, more sites than we probably have patients need for. That's the best practices when it comes to executing in rare disease. Right now, we are open in the U.S. as well as two non-U.S. regions as well. First half of next year, we'll provide a little bit more metrics on enrollment and timelines, so that you guys can start putting a dot in the ground on when the data comes.
Okay. Yeah, that's helpful. I think we're estimating you could potentially get the data in like second half of 2028. Do you think that's a reasonable timeframe or?
I usually kind of remind you of the two times three by 2030.
Yeah.
There will be two commercial programs in 2030. Sooner is better.
Right.
Two late-stage programs, two early-stage programs. If we are getting close to that, we have built a really significant multi-product company.
Right. Okay. Wondering if FDA gave any specifics on how the results would be reviewed. Were there any statistical thresholds defined for efficacy, and what do you need to show to get clear conviction?
Yeah. Nothing has changed here. We have been aligned for a long time. We want 90% power to show minimum 50% reduction. You know that if you low in the intention to treat analysis in our phase II, we got to 50. In the per-protocol analysis of the low-dose weekly regime, we see about 80% reduction. We feel really confident that we've designed a registrational trial that certainly has the potential to yield really compelling results.
Got it. If you hit your best or base case efficacy scenarios, how will this translate to market opportunity, and how will you price this drug?
Yep. I think that's another part of, we have not tried to reduce variability by developing kind of unrealistic eligibility criterias that eventually could result in a narrow label, and thereby generate restrictions. The way it's designed is really to kind of embrace as many of the Glanzmann patients as possible. So if there's 800 to 1,000 patients in the U.S., on the other side of this trial, the vast majority of them will be eligible.
Got it. Okay. On pricing, is there anything you're saying on that at this point?
Nothing has changed. I think we keep on saying if you want a reference point
Yeah
we think a good reference point is the price tag of HEMLIBRA.
Yeah.
The list cost is about $800,000 per patient per year. Adjusted for weight brackets, it's probably average around $650,000. That's a base case. I think I've heard about 15 times today, but Glanzmann is more rare. There may be a higher unmet needs. Let's have a look at that. It's much easier to adjust things up than down.
Right. Yeah. Yeah, makes sense. For Factor VII, you're going to have an updated data cut at ASH from your phase II-B.
What's going to be new in that update, and what is the magnitude of partial thromboplastin time shortening in Factor VIIa accumulation you want to see to expand the study to more sites?
Yeah. This is the first ever clinical data of sutacimig in Factor VII deficiency. I'm super proud of this because it's such a demonstration of the power of translational coagulation biology. What we have said in the abstract is we see up to five-fold increase in total VII. We see more than a 50% reduction in the prothrombin time. I think this is important because we have actually, in a small number of patients, pretty much recapitulated our entire preclinical package. We've also leveraged our deep understanding of the molecular biology of Factor VII deficiency. Based on knowing the mutation, builds a data package that actually can predict whether you are going to be a responder or not a responder.
So, for the first time in coagulation biology, we can actually use the molecular knowledge to guide whether you're going to benefit or not. I think that's pretty cool.
Yeah. Yeah, interesting. For this study, I guess, what are the next steps going to be, and what do you think about the development path there and some of the options?
Yeah. We kind of, and it is so appropriate to be here in London, we did the first couple of patients just one site here in the U.K. The data we have generated are really, in our eyes, binary in a way that this justifies increasing the investment, opening additional countries, additional sites. We obviously need to generate some volume in the data before we can land final dose-dose regime. If we actually let the Glanzmann study advance a little in the background, we can leverage some of that safety data going forwards and maybe generate a little bit more of a lean strategy in Factor VII deficiency.
Okay. Interesting. How many Glanzmann and Factor VII deficiency patients do you think are underdiagnosed, or undiagnosed, or undertreated because of lack of prophy options, and is there a large latent patient population that could emerge?
Yeah. Maury, I feel like we have had this discussion a couple of times. We know there is 10,000 patients in U.S., Europe, Gulf States, Japan, and a small part of rest of world, which combined with Glanzmann's and Factor VII deficiency. The question is there a hidden population? I do not think it is like, for instance, PNH, where in the early days of Alexion's journey to make a first-ever prophy, it was probably one in a million. Now it is like, on national TV, it is easily 10 times higher prevalence. I do not think that is the case for Glanzmann and Factor VII deficiency. I think that there will always be a pocket of a percentage of patients that are not known or has been lost in the system because there was not modern therapies.
I will say, though, there is a potentially interesting added opportunity in Factor VII deficiency.
The 5,000 patients with Factor VII is assuming we are only targeting the most severe. If the drug is safe and efficacious, I can easily imagine that you would start treating patients with moderate, and that could boost the numbers very significantly.
Got it. What does that look like again?
The rare is like one in 500,000.
Yeah.
The moderate's like one in 20,000.
Got it.
It's much more prevalent.
For sutacimig, are there other opportunities beyond?
You know what? You can somewhat say the clinical validation by NovoSeven has generated almost like a GPS roadmap for sutacimig. Now it's Glanzmann, it's Factor VII deficiency. We can go to Bernard-Soulier, we can go to other platelet disorders. Of course, this is a treatment that also will have effect in the very treatment-resistant hemophilia A and B. I know this sounds like a cliché, right, but it has the opportunity of being a bit of a pipeline within one drug.
Right. Yeah. Yeah. Interesting. Your second asset is HMB-002 for von Willebrand disease. You've shown some early safety data, but a more robust update is expected at EAHAD in February. Where are you at with dosing in the SAD and MAD phases at this point?
Yeah. We've shown data from three cohorts at ISTH in July, 20 mg, 50 mg, and 150 mg, total of 13 patients. The drug is doing what it was designed to do. We see nice dose proportionality. The higher the dose, the longer the duration of effect. We see really compelling increases in von Willebrand factor and factor VIII, give or take, 2.5-fold increase. This is a fun fact. When we started this journey, we were convinced if we get 1.5-fold, we have a really successful drug. Now we have 2.5-fold. Actually, on average, we are normalizing levels of von Willebrand factor and factor VIII in the population we have studied. Thinking about that as a clinician, this is a super compelling profile.
Yeah.
That you can measure levels, give a drug, you can measure the effect, and if-
Right
they're in the normal range, your advice to these patients is, "Go home, live your life.
Yeah.
That is just so exciting.
Right.
That's where we are. That's 13 patients. Come EAHAD in February, we will add an additional 300 milligram dose cohort in the single ascending dose, and we will show the first data emerging out of the 150 milligram monthly multiple dose.
Got it. Okay.
Total number of patients, Maury it's like, it's eight to 10 additional patients. So now we have nicely over 20 patients worth of data to start generating, I think, a total look into data. People are often asking, "What is your number one variable that you're excited about?" I think if we can continue to see a red line between PK translating to PD, translating to coagulation activity, and actual clinical observations, we will be super excited.
Yeah. Makes sense. For this program, you've got approximately 110 patients in your prospective natural history run-in-
VELORA study. What magnitude of ABR reduction in your ongoing study, versus the run-in in VELORA, would you view as sufficient to move 002 into registrational study?
Yeah. So by the way, I think the VELORA Discover, we've not talked a lot about it. I'm not sure we're going to talk a lot about it because it actually generates a goldmine of highly proprietary data, understanding what is the characteristics of the clinical phenotype of von Willebrand disease, in particular type 1, type 2A, constituting the vast majority of the patients. Getting an insight into what fraction of those patients are actually bleeding very frequently, what's their characteristics, what's the variability in bleeds, all of those things that can actually enable us to do a really powerful, successful pivotal trial. Therefore, we're not going to talk a lot about it, because that would be giving away important information.
Got it.
I think your question was, what reduction in Remember, we are looking at prospectively collected annualized treated bleeds, so they have real clinical significance. There are accountability built in, because the second you treat, you can go back and verify that the treatment has been given. And in our kind of correspondence with payers, it's pretty clear that treated bleeds are reimbursable bleeds.
Not treated bleeds is, "Don't pay for that." We are collecting that data. In von Willebrand disease, as a minimum, you want to see at least 50% reduction.
Right.
More is better.
Yeah.
But I think at this early stage, that's the right guidance. We want to have a very clear signal in effect. I know that every single good analyst, including yourself, would be like, "Ah, what exact number do you want to get to?" It's going to be preliminary still.
Yeah.
I wouldn't really put my head on the block on a certain number.
But comparing to VELORA, basically you're saying that's not going to be possible because you're not going to share any data from that study.
Well, the patients that enroll into the phase II, of course we will show that data.
Yeah.
We don't show population-based data.
Yeah
Because that is really a trade secret.
Right. Yeah.
for the company.
Yeah. Makes sense. You're saying you want to see all the measures align, so PK, PD, and then see the bleeding reductions.
Yeah.
Potentially the 50% bar is what you've mentioned. I guess, how do you contextualize this versus the Insight Star data?
Yeah
where they showed approximately 80%, but it was in a small number of patients?
Sure. It is a totally fair question, how do you compare? Unfortunately, the way each of us have made strategic decision conducting these trials makes that comparison pretty much impossible. Insight is collecting baseline data based on patients' individual retrospective recall, and they are asking them to estimate total number of bleeds, irrespective of whether they were treated or not. Our approach is patients are being enrolled in a prospective trial, fully GCP monitored. We are prospectively collecting that for a minimum of four months. Those two variables are just not comparable at all. Therefore, you can show 80% here, and you cannot compare that to a reduction in our data set.
Yeah.
I think one of the real strengths that we have is, this is a treatment that you can monitor. If a patient comes in, he has 20% von Willebrand factor and 35% factor VIII, you can give HMB-002, and then a week later, you could invite the patient in, and you can monitor if you have got effect.
Right.
I think that is really compelling.
Yeah. You'll be able to know if you're having an effect in these patients, so you'll determine that information for seeing longer term follow-up for these patients. I guess, when does that become more meaningful over time?
Yes. I think all of them will have minimum four months baseline. We will have up to four months of follow-up on treatments in the multiple dose. You can ask, when is the number sufficient to generate a good quantitative estimate? I don't think first cohort is like that. But hey, there's good interest in the trial. I'm convinced that in 2027, we'll get to an understanding on all what is needed for us to transition to the next stage.
Right.
I think everybody should expect that from phase I/II, it is transitioned straight to a single pivotal trial.
Okay. That's helpful. While we're still on the topic, with the Insight drug, VGA039, maybe just talk about how your drug compares with that.
Yeah
What do you expect them to show in their longer term data at ASH?
Yeah. Even though we are, by the way, we see a little bit ourselves as collaborators with Insight, because we are both generating a lot of awareness and interest in von Willebrand disease, and we are kind of coming at it at really distinctly different angles. HMB-002 is designed as a monovalent antibody. It targets endogenous residual von Willebrand factor. It generates a high-affinity binding, so it's almost like an in vivo half-life extension of von Willebrand factor. That then leads to an increase in von Willebrand factor and increase in factor VIII. So, from a mechanism of action point of view, it is really intuitive and simple. We directly target, we directly correct the underlying pathophysiology.
Our friends at Insight is kind of pursuing this from a more experimental therapeutic hypothesis point of view, investigating if inhibition of a natural anticoagulant like protein S can bypass von Willebrand factor and bypass factor VIII. I actually, first and foremost, believe in innovation. It's good for patients, it's good for competition. I'm sure there will be patient pockets that will benefit from that treatment strategy. I'm super biased, Maury. I believe many more patients will benefit from HMB-002.
Right. Yeah. That makes sense. You mentioned potentially moving from the phase I/II directly into a phase III study.
Yeah.
When do you expect the end of phase II FDA interaction to take place, and how quickly?
Yeah. You know what? Let's see the next batch of data, and I think we can provide a little bit more data-driven guidance on when we think we can be in a position to transition. Meanwhile, VELORA Discover remains open, and we will build a repository of patients with baseline data. There's no doubt that you need to really understand with high-quality data what's the baseline bleed rate.
Right.
You got to have eligibility criteria so there is significant enough bleeds to actually see a treatment effect.
Yeah. Going back to the broad treatment and what you think you could treat with HMB-002, with this disease, there's a lot of heterogeneity. Which subtypes do you think would respond best to HMB-002 versus VGA039?
Yeah. HMB-002, with the data we have already, a high degree of confidence in all type 1. At EAHAD in February, we will show data both in type 1 and type 2A. If you think about it, 80% of patients have type 1. Another 10%-15% of patients have type 2A. So, if we can convince ourselves we have effect in those two, we are looking about 90%-95% of all patients with von Willebrand disease. The remaining 5%, it's a little bit of a mixed bag, type 2B, 2M, 2N, and of course, a very small pocket of type 3. As part of our phase I/II, we will look into co-administering HMB-002 with a von Willebrand factor concentrate. Not that 250 or 300 patients in the U.S. can kind of move the business case, but we know the physicians would do this.
I think it's a cool experiment to do. We will generate that data. For now, the focus is really on type 1, type 2A. It constitutes the vast majority of patients.
Got it. When would you be able to generate the data with the von Willebrand factor?
We'll let you know.
Okay. Let's shift gears. We'll talk about your third program.
Yeah.
HMB-003. It's entered the clinic, healthy volunteers. Key competitor is Alnylam, targeting upstream with their siRNA. Can you compare and contrast your approach versus Alnylam's and where you can see differentiation show up on safety in particular?
Disclaimer, right? Previous Alnylam employee. I may say something nice about them. First and foremost, let's think about the way we have engineered HMB-003. Plasmin as a target, it's a clinically validated target in heavy menstrual bleeding. It's also a genetically validated target in heavy menstrual bleeding. So, a high degree of conviction that that's the right target if you want to control heavy menstrual bleeding. From a modality point of view, we've used a fatty acid conjugated peptide, same technology framework as GLP-1s. It really has pharmacokinetic properties that are ideal for heavy menstrual bleeding. One subQ shot, within very few hours, you have Cmax, so you very promptly get max pharmacological effect. It's engineered with fatty acid compositions to kind of then have the most pharmacological effect during the early days of the menstrual bleed and then fade out again.
The fade out is super important because what we know from congenital plasminogen deficiency is constant inhibition of plasmin can lead to really serious extravascular fibrin depositions. They can be easy to see. You can see them in the eye and the mouth. But for women, those extravascular fibrin depositions can occur in the cervix and the fallopian tubes. Just at ISTH in July, population-based data in plasminogen deficiency showed that 40% of women with plasminogen deficiency become infertile.
It's kind of, for us, recovering plasmin so that you can clear all of those extravascular tubes is absolutely essential. The siRNA technology, right, it's potent, it's durable, extremely durable, and it will lead to kind of an acquired plasminogen deficiency-like state. I think the benefit-risk in HHT makes good sense. Maybe a little harder to kind of understand benefit-risk in heavy menstrual bleeding, in particular, if there's a risk of infertility. The challenge with infertility is you can't see, right? So you can't monitor if your fallopian tubes are getting clogged up.
Hmm. Yeah, interesting. You're going to have some NHP data at ASH.
Yeah.
Maybe talk briefly about the findings there and how translatable you think the data is.
Yeah. By the way, I think one of the coolest pre-clinical experiments we've done, we've followed a group of female non-human primates, identified those that have regular menstrual bleeds, further selected for those who have a severe bleeding rating, generated a baseline, and then put them on HMB-003. In the abstract, we are saying we can see a very distinct reduction in the severe bleed days, and we'll show the actual quantitative data there. Is that translatable? It's the closest we can get to a pre-clinical model of kind of a registrational trial in heavy menstrual bleeding.
Yeah.
Super excited about that. I think it's a good initial look into what to kind of expect.
How much follow-up do you have on the NHPs?
It was a very long study. There's a minimum of two periods before, two periods after treatment.
Got it. Interesting. Then for your initial healthy volunteer data in mid 2027, what are you going to show there, and how quickly can you get this program into later stages?
Yeah. Right now, it's a randomized placebo-controlled trial in healthy volunteers. It's safety PK. PK is important because part of the targeted product profile is to confirm that we have pharmacokinetics that supports a one subQ shot. The PD is actually very informative as other studies done with plasmin inhibition, like tranexamic acid. We can see what was effective in those trials, and we can use the PD to kind of say, "Okay, this is the dose that is going to give the most favorable effect." Usually phase I studies is a little boring, but in this particular case, I actually think the totality, both PK and PD, can be quite exciting.
Got it.
Yeah.
I didn't realize we had a minus sign in front of our-
Oh
timer here.
I don't like minus.
Since we're over on time, maybe just to close out, if you could talk about pro forma cash and runway assumptions, and then key catalysts ahead.
Yeah. There is nicely more than $400 million in the bank, runway well into 2029. There's a lot of data coming up. ASH, we have Factor VII deficiency data. In February, we have von Willebrand disease data, and in mid 2027, we have the first data on HMB-003. We can populate the remainder of the calendar year with more data later.
Okay. Well, great. Thanks so much for joining us today, Benny.
Awesome. Thank you, Maury.